Creative Planning
CRVS icon

Creative Planning’s Corvus Pharmaceuticals CRVS Stock Holding History

Creative Planning’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$630K Sell
42,174
-858
-2% -$11.9K ﹤0.01% 3007
2026
Q1 		$630K Buy
43,032
+3,854
+10% +$61.5K ﹤0.01% 2842
2025
Q4 		$302K Buy
39,178
+13,879
+55% +$109K ﹤0.01% 3232
2025
Q3 		$186K Buy
+25,299
New +$129K ﹤0.01% 3517

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Creative Planning's CRVS Position: Q2 2026 in Review

Creative Planning reduced its Corvus Pharmaceuticals (CRVS) stake by 2% in Q2 2026, selling an estimated $11.9K and leaving 42,174 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

Creative Planning first reported a position in CRVS in Q3 2025 and has held it in 4 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Creative Planning held 42,174 shares of Corvus Pharmaceuticals worth $630K as of Q2 2026.
  • Creative Planning sold 858 Corvus Pharmaceuticals shares in Q2 2026, an estimated $11.9K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3007 holding.
  • Creative Planning first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.